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Acute renal failure due to glomerulonephritis in patients over 60.
Interest of renal biopsy. Y. Tanter, P. Dubot, C. Mousson, E. Justrabo,
A. Bonnin, B. Jonon. J. M. Chalopin, G. Rifle, Departments of
Nephrology and Pathology. University Hospital, Dijon, France.
Oligoanuric acute renal failure (ARF) is not rare in the elderly. Between
1980 and 1986, we treated 273 patients with ARF. Among them 142
(52%) were over 60 years. Renal biopsies were performed in 40 patients
(28%) when we suspected glomerulonephritis (GN) (proteinuria > 2
g/liter, macro- or microscopic hematuria), or systemic disease, or when
no etiology was obvious, or when diuresis did not increase at the end of
the fourth week. No side effects occurred. In 22 cases (55%) the biopsy
only showed acute tubular and interstitial nephritis, including I
myeloma and 1 secondary oxalosis. In 1 case, we observed amyloid
nephropathy. In 17 cases (45%), glomerular lesions were isolated or
dominant. They were found in 9 women and 8 men (mean age: 69 4.2
years). In 13 cases we noted extracapillary proliferation (RPGN)
associated with mesangial proliferation in 3 patients. This lesion seemed
idiopathic in 8 cases and was associated with necrotizing angeitis in 5
cases. Two cases were membranoproliferative GN; one of them was
associated with type II cryoglobulinemia. One patient had IgA mesan-
gial GN and another one minimal change GN. In addition to dialysis,
despite being elderly patients, specific treatments, according to diag-
nosis, were used: methylprednisolone pulses (15 mg/kg/day) and corti-
costeroids (I mg/kg/day), immunosuppressive drugs (cyclophospha-
mide) and/or plasma exchange. In 9 cases (53%), of them 3 RPGN, renal
function improved, and patients were off dialysis with a follow—up of 6
months to 6 years. One patient is still on dialysis after 1 year. Seven
other patients died, 5 in the first 2 months (5 RPGN). The treatments
were not immediately responsible for death. One died of myocardial
infarct during a third relapse of RPGN. The last patient died 18 months
after starting hemodialysis. This study emphasizes the need for inten-
sive investigation of ARF whatever the patient's age. Indeed, incidence
of ON is at least as high as that in younger patients. RPGN is frequent
in this series, as in others, and precise histological diagnosis has
permited us to set up treatment that is both specific and efficient.
Treatment of refractory congestive heart failure by continuous perito-
neal dialysis. C. Mousson, V. Tanter, J. M. Rebibou, P. Morelon, G.
Dentan, J. M. Chalopin, G. Rifle, Department of Nephrology and
Reanimation, Department of Cardiology, University Hospital. Dijon,
France. Continuous ambulatory peritoneal dialysis (CAPD) was used to
remove fluid in refractory congestive heart failure (HF). Patients and
methods. We included in this study 18 patients (P), 13 men and 5 women
(age range 39—77 years, mean 60.2). Primary cardiac disease was:
valvular disease 7 P, coronary heart disease 7 P. amyloidosis 2 P,
primary dilated cardiopathy I P, primary pulmonary hypertension I P.
All patients had NYHA class IV dyspnea, requiring oxygen and even
mechanical ventilation in 3 P. Cardiothoracic ratio (CTR) ranged from
0.53 to 0.80 (mean: 0.62). All patients had pulmonary alveolar edema,
ascites and gross edemas. Systolic blood pressure (SBP) ranged from 50
to 90 mm Hg (mean: 72). Left ventricular ejection fraction (LVEF)
ranged from 14 to 54% (mean: 32). In all cases, HF was intractable
despite treatment with vasodilatators, large doses of furosemide,
inotropic agents and fluid intake restriction. Seven of them had previous
organic renal failure (ORF); serum creatinine level (SCL) ranged from
200 to 500 mol/liter during the 3 previous months. Eleven P had
normal renal function or functional renal failure (FRF) due to low
cardiac output. CAPD was carried out using standard techniques (K,
3—5 mmol/liter into dialysate). All patients received i.v. heparin. Re-
sults. Eight P (44%) died before the end of the third week, 6 had
ventricular arrhythmia, 2 had sepsis of urinary tract or digestive origin.
Weight loss ranged from 2 to 10 kg (mean: 7). Ten P were still alive 1
month after starting CAPD and 9 of them were discharged. Weight loss
ranged from 4 to 41 kg (mean: 14). Mean CTR decreased from 0.61 to
0.55. Surprisingly, no significant improvement of LVEF was observed.
Dyspnea improved to class H in 6 P and to class III in 4 P. Mean SBP
improvement was 20 mm Hg despite discontinuing inotropic agents. Six
of these 10 patients died between 2 to 27 months (mean: 9.5) after
starting CAPD. Causes of death were: ventricular arrhythmia, 3 P;
undernutrition, 2 P; cardiac arrest at home 24 months after discontinu-
ing CAPD, 1 P. CAPD was stopped in 2 of the 10 patients, who had
increased diuresis (normal initial renal function). These 2 P then
survived from 4 to 24 months before dying (I ventricular arrhythmia, I
cardiac arrest), SBP, CTR, fluid overload, LVEF, ORF were not
predictive of survival. However, initial nutritional status, the need for
mechanical ventilation, amyloidosis and patients who are more than 70
years old seem to indicate poor prognosis. Conclusion. CAPD allows
long and good quality survival in some patients whose initial status is
very serious. Mortality might be lower if these patients were treated
earlier. This trial needs to be continued, particularly in patients awaiting
graft.
Lack of antireticulin and antiendomysium antibodies in patients with
primary tgA nephropathy associated with IgA antibodies to gliadin. G.
Rostoker, C. Andre, A. Branellec, S. Bourhala, J. Laurent, G. Lagrue.
Department of Nephrology and Hematology, Inserm U 139, Hôpital
Henri—Mondor, Creteil (940/0), France. The association of circulating
lgA antibodies to gliadin (J. Laurent, Am. J. Nephrol in press) and the
decrease of IgA-containing immune complexes on gluten—free diet (R.
Coppo, Clin Nephrol 26:77—82, 1986), suggest a possible etiologic role
for wheat gliadin in primary IgA nephropathy (ON IgA) and a possible
association with a latent coeliac disease (CD). Antireticulin and IgA
class antiendomysium antibodies are specific immunological markers
for CD and dermatitis herpetiformis associated with CD. Antireticulin
antibodies were sought in 16 patients having GN IgA with permanent
proteinuria (> 1 g/24 hr) and IgA antibodies to gliadin, whereas
anti-endomysium antibodies were sought in 4 of these patients. No
patient exhibited these autoantibodies. These results and the normal
results of the gut absorption test with radiolabelled EDTA and of the
jejunal biopsy performed respectively in 5 and 3 IgA GN patients
(personal results, unpublished data) suggest that IgA GN is not associ-
ated with latent CD. The relationship between wheat gliadins and IgA
GN remains hypothetic and needs further investigation.
Enhanced levels of beta-2.microglobuline (132m) in lymphocyte culture
supernatants: A marker of lymphocyte activation in idiopathic nephrotic
syndromes (INS)? R. Robeva, A. Branellec, J. M. Heslan, P. Lang, G.
Rostoker, M. A. Pech, G. Lagrue, Hopital Henri Mondor, INSERM
U139, Créteil, France. INS is associated with a disorder of T lympho-
cyte (L) functions and an enhanced production of a lymphokine, the
Vascular Permeability Factor (YPF). But VPF is measured by a
biological assay (Ovary's method) which is time consuming and some-
times difficult to interpret. It would be important to have an indirect
method for investigating L activation. /32m is secreted by L and tumor
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cells and is considered to be a marker of these cells' activity. However,
in autoimmune diseases elevation of /32m serum levels is less than in
lymphoproliferative disorders and cancers. We therefore investigated
/32m levels in L culture supernatant. In 21 active INS, f32m levels in
unstimulated L cultures were significantly increased in comparison with
those of 15 controls (median 25.5 ng/ml vs. 15 ng/ml, P < 0.05, Mann
Whitney test); 9 cases had levels higher than upper limit of normal. In
14 prednisone (P) treated INS, f32m levels were lower than before
treatment (median 13.5 ng/ml, P < 0.001) and lower in cases with
complete remission than in cases with persistent proteinuria. /32m levels
were also lower in 13 cyclosporine (C) treated INS (median 10.5 ng/ml,
P < 0.01) and in 10 INS in complete remission, without treatment(median 10.5 nglml, P < 0.05). In vitro the addition of C (100 ng/ml)
inhibited the f32m elevation observed in INS. The same differences
between various groups were observed with Con A stimulated L, with
higher f32m levels. Correlation between /32m level and VPF activity was
not significant (r = 0.44, P < 0.1), but there were too few cases studied
simultaneously. High levels of f32m in supernatant of L culture from
INS are conditioned by enhanced cellular synthesis and inhibited by P
or by C. Whether this /32m hyperproduction is the mere reflection of L
activation or plays a pothogenic role in the immune process is still
speculative.
Immunological abnormalities in hemodialysis patients affected by a
carpal tunnel syndrome (CTS). K. S. Ang, P. Simon, Y. Y. Cavarle, G.
Cam, N. Genetet, M. Catheline, Service de Nephrologie, CH La
Beauché Sant—Brieuc, Laboratoire de Biochimie B CHU Pontchaillou
ef Laboratoire dimmunogenetique CRTS Rennes, France. /32microglo-
bulin amyloidosis (/32mA) is a prominent feature of the CTS in uremic
patients undergoing long—term hemodialysis (HD). The pathogenesis of
B2mA is still unknown. Impaired cellular immunity which is dependent
on the duration of end—stage renal disease, and hemodialysis therapy
might be determinant among the factors potentially implicated in the
occurrence of /32mA. Eleven uremic patients, 5 with CTS (Group A)
and 6 without (Group B) undergoing HD from 8 to 21 years (mean 12
5 yrs for A and 8.5 1.9 yrs for B, NS) were studied. Control blood
samples were obtained from 5 age— and sex—matched healthy volunteers
(Group C). The present study investigated the serum levels of IgG, 1gM,
IgA, the cutaneous tests and the peripheral lymphocyte subsets which
were measured using monoclonal antibodies. The changes which oc-
curred during dialysis procedure using cuprophan (CUP) and non-
cuprophan (AN69-PAN) membranes were also studied. The following
results were observed (A vs. B): (1.) the absolute numbers of OKT3 +,
OKT4 + cells were significantly lower in HD patients than controls and
in Group A than in Group B; OKT3 (m sD/mm3), 387 253 vs. 744
207, P = 0.03; OKT4, 262 115 vs. 589 297, P = 0.04. (2.) At the
end of HD, the relative proportion of OKT3 + and OKT4 cells
increased with AN69-PAN and decreased with CUP. (3.) In the
interdialytic period, serum levels of IgG and 1gM were significantly
lower in patients with CTS than in controls and HD patients without
CTS;IgG(m SD/g/liter):l0.2 1.4vs. 15.4± 3.2,P<0.0l;IgM:0.65
0.28 vs. 1.65 0.37, p 0.001. 4) delayed hypersensitivity studied by
cutaneous tests showed < 3 positive antigens in 4 of 5 patients with CTS
against I of 16 patients without CTS. These data suggest the association
of severe deficiency of T helper cells with hypogammaglobulinemia and
anergy in HD patients affected by 132m amyloidosis.
Histamine release during hemodialysis. P. Deteix, G. Betail, A.
Tridon, G. Gail/ard, A. Marques—Verdier, P. CIuzel, J. P. Wauquier,
J. C. Alphonse, J. C. Baguet, Service de Nephrologie, CHU St
Jacques, Laborato ire d'Immunologie, Faculté de Médecine,
Laboratoire 'in vitro" Centre Jean Perrin, Laboratoire d'hématologie
CHU St Jacques, C/ermont—Ferrand, France. The biocompatibility of
a new cellulosic membrane, Hemophane (HE), was compared to that of
a reference membrane Cuprophane (CU), with respect to different
biologic parameters, including plasma histamine. Ten chronical-
ly—hemodialyzed patients were studied. Each of them was dialyzed on
each of the two membranes, in random order. Blood was collected at
four times during the dialysis procedure: 0, 10, 20 and 180 minutes.
Leukocytosis was measured with Technikon H6000. The C3a-desARG
anaphylatoxin and plasma histamine were assayed by RIA. There was
a more important increase on C3a with CU than with HE (14-fold and
3-fold predialysis values). There was a transient leukopenia only with
CU. Plasma histamine level significantly increased during dialysis with
CU (peak level 2.04 1.47 ng/ml), while no change was observed with
HE (P < 0.05). Likewise, basophils decreased by 53% with Cu and only
20% with HE (P < 0.01). Thus, basophil and/or mastocyte activation by
the anphylatoxins generated from trigering of the alternative pathways
of complement is likely to be responsible for hsitamine release. Hista-
mine could be involved in hypersensitivity reactions observed in some
dialyzed patients and the possible release of other mediators of
anaphylaxis by basophils and mastocytes deserves further investiga-
tion.
Free and total catecholamines in patients with chronic renal failure on
hemodialysis. F. Cogny—Van Weydevelt, J. P. Charmes, G. Lachatre,
M. Benzakour, G. Nicot, C. Leroux—Robert, Services de Nephrologie
et de Pharmacologie Clinique, Hôpital Universitaire Dupuytren,
Limoges, France. A defect in the autonomic nervous system in dialysis
patients is now well accepted. This consists principally of a defect in
baroreceptor sensitivity. To evaluate the autonomic nervous system in
dialysis patients we measured plasmtt concentrations of free and total
norepinephrine (NE) and epinephrine (E) and total dopamine (DA)
using HPLC in 18 patients dialyzed with a cuprophan membrane (11
men, 7 women; mean age: 58.6 years). Before dialysis, plasma concen-
trations of free NE and E, and more particularly, of total NE, E and
DA, are significantly higher than in normal subjects (P < 0.05). After
dialysis we observed a reduction in total NE, E, and DA plasma
concentrations although these remained higher than in normal subjects,
and a significant increase in free NE and E plasma concentrations. The
persistent increase of these sympathetic nervous system activity iaark-
ers with, in particular, increased free and therefore active NE and E
plasma concentrations after dialysis, could represent an important
factor of vascular risk in chronic renal failure patients on hemodialysis
by a direct vascular effect and modification of lipid concentrations.
Nephrogenic diabetes insipidus and distal tubular acidosis in meticil-
un—induced interstitial nephritis. Ph. Vigeral, A. Kanfer, S. Kenouch,
B. Mougenot, F. Blanchet, J. Ph. Méry, Service de Nephrologie and
Laboratoire d'Exp/orations Fonctionnelles, Hôpital Bichat and
Laboratoire d'Anatomie et de Cytologie Pathologique, Hôpita/ Tenon,
Paris, France. Distal tubular abnormalities were demonstrated in two
patients in whom meticillin induced interstitial nephritis with renal
failure. Some degree of renal insufficiency persisted in both patients
after the acute episode. The first patient was explored because of
polyuria and metabolic acidosis, 2-1/2 months after onset of nephrop-
athy when plasma creatinine was 240 mol/liter. Diabetes insipidus (DI)
was demonstrated after 12 hours of complete fluid restriction: urinary
osmolality (Uosm), 528 mOsm/kg (N > 800 mOsm/kg); urinary volume
(V), 1.22 mI/mm (N <0.5 mI/mn); free—water clearance (CH2O), — 0.93
mI/mm (N < — 2 mI/mn). These abnormalities were not corrected after
DDAVP injection, and plasma ADH was 16.9 pg/mI (N: 3.6 0.8 pg/mI)
showing that DI was nephrogenic. Distal tubular acidosis (DTA) was
demonstrated by a bicarbonate loading test showing an abnormally low,
urine—blood pCO2 gradient of 16.7 mm Hg (N > 30 mm Hg). The second
patient was explored because of polyuria (4 to 6 I/days) 7 months after
onset of nephropathy when plasma creatinine was 213 tmol/liter; there
was no metabolic acidosis in this patient. Nephrogenic DI was also
demonstrated. After fluid restriction, Uosm was 263 mOsm/kg; V. 1.71
mI/mm; CH2O, + 0.23 mI/mm; absence of correction of these abnor-
malities after DDAVP injection; plasma ADH of 8.2 pg/ml. In conclu-
sion, these data show that meticillin—induced interstitial nephritis may
result in persistent nephrogenic DI and DTA.
Correction of dialysis anemia by recombinant erythropoietin. B. Zins,
J. Zingraff, F. Peter/on go, L. Bererhj, C. Naret, H. Kreis, N. Casade-
va/I, B. Varet, J. P. Castaigne, T. Drbeke, Necker and Cochin
Hospital, E. Rist Center and CILAG Lab., Paris, France.
Erythropoietin deficiency is one of the major causes contributing to the
anemia of chronically uremic patients maintained on long—term hemo-
dialysis. We investigated the effect of thrice weekly intravenous admin-
istration of recombinant human erythropoietin (rHuEpo) on the anemia
of 11 non-transfusion—dependent, chronic hemodialysis patients with a
follow—up of at least two months. rHuEpo was provided by Ortho, Cilag
and Amgen laboratories, USA and France. Initial dose was 24 lU/kg
body weight. It was increased every two weeks by doubling the
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previous dose when hemoglobin (Hb) rise was less than 10%. Hb
increased from a mean value of 7.5 1.2 (±sD)to 9.3 1.2 g/dl at two
months (N = 11,? <0.001). This increase was preceded by a significant
rise of reticulocyte count. Only one patient did not respond to therapy.
The most recently available mean Hb value achieved by the 10
responders is 10.2 1.7 g/dl (±sD). The only non-responder remained
stable at 9.3 g/dl after 11 weeks, although he received the highest dose
of rHuEpo (384 lU/kg) administered as yet in this study. None of the 10
patients responded to 24 lU/kg. At present, 2 of 10 patients reached the
Hb value of 12 g/dl, which was the objective of this clinical trial, after
17 and II weeks of treatment, respectively. Their pretreatment values
were 5.3 and 9.0 g/dl. One normotensive patient with a prior history of
convulsions presented with a hitherto unexplained seizure episode and
a transient hypertensive crisis when his Hb level reached only 10.3 g/dl.
He then received 96 lU/kg of rHuEpo thrice weekly. In conclusion,
thrice weekly administration of rHuEpo appears to be an efficient
treatment allowing to obtain an improvement or even correction of
anemia in chronic hemodialysis patients. Particular caution should be
devoted to patients with a prior history of convulsions. The possibility
of a resistance to rHuEpo in a subset of dialysis patients should be given
further consideration.
Piridoxilate—induced oxalate nephropathy: A new variety of nephrocal-
cinosis. Ph. Vigeral, S. Kenouch, D. Chauveau, B. Mougenot and
J. Ph. Méry, (.'ervice de Néphrologie, Hdpital Bichat and Laboratoire
d'Anatomie et de Cytologie Pathologiques. Hôpilal Tenon, Paris).
Several cases of calcium oxalate nephrolithiasis presumably due to
hyperoxaluria have been recently reported in patients chronically
treated with piridoxilate (P), a combination of glyoxylic acid and
piridoxine. One of the metabolic pathways of glyoxylic acid is indeed
oxidation into oxalic acid, It seems that oxalate nephropathy with renal
insufficiency may also be induced by chronic (P) administration. This
70-year—old man had been taking (P) 450 mg daily since 1976 because of
coronary disease. In April, 1985, serum creatinine was 168 moI/liter.
In June, 1985, a radio—opaque stone was demonstrated in the right
inferior calix. Shock—wave lithotripsy was then performed and was
followed by elimination of small fragments of stones made of
whewellite. In October 1985, when the patient was still taking (P), daily
urinary elimination of oxalate was 522 mol (N < 330 smol) and an
early morning urine sample contained numerous crystals that infrared
spectrometry showed to be whewellite. Serum creatinine was 329
smol/liter. Renal biopsy showed chronic tubulo-interstitial nephritis
with numerous intraluminal and intracellular crystals in he tubules
which were birefringent when viewed under polarized light. (P) was
then withdrawn. One month later, oxaluria was 110 mol/day and
crystalluria had disappeared. Serum creatinine was 334 mol/liter. In
conclusion, this observation shows that long—term treatment with (P)
induces hyperoxaluria which in turn may result in calcium oxalate
nephrolithiasis and chronic oxalate nephropathy.
Massive removal of antidiuretic hormone from plasma during
hemofiltration stimulates its secretion in humans. B. Viron, W.
Pruszczynski, F. Mignon, R. Ardaillou, INSERM 64, Hôpital Tenon,
Paris, France. Antidiuretic hormone (ADH) was measured in the
plasma and its ultrafiltrate in 11 patients with end—stage renal failure.
The patients were hemodialyzed in order to obtain a state of normal
hydration. Then high—rate hemofiltration was started using a
polyacrylonitrile membrane. Nineteen liter of ultrafiltrate were pro-
duced in 170 minutes and continuously replaced by an isoosmotic
substitution fluid to maintain constant weight. ADH concentration was
not significantly different in the plasma (7.1 0.4 and 7.4 0.6 pg/mI
before and after hemofiltration) and in the ultrafiltrate (6.6 0.5 pg/mI).
It did not change during the session and the following 24 hours. Total
extracted ADH calculated from either ADH present in the ultrafiltrate
or the difference between ADH entering and leaving the ultrafiltration
system was 131 lOng. The corresponding ADH clearance was 114
2.6 mI/mm, which represented more than two-thirds of the metabolic
clearance rate of the hormone as predicted from previous results
obtained in this laboratory. Plasma osmolality, body weight, blood
pressure and plasma renin activity were not modified during
hemofiltration. These results demonstrate that ADH is freely filtered
through the membrane studied and thus does not bind to plasma
proteins. Furthermore, they indicate that ADH secretion is adequately
stimulated in order to maintain plasma levels constant despite the
increase in the metabolic clearance rate. We advance the hypothesis
that ADH secretion increases rapidly in response to hemofiltra-
tion—induced ADH removal through a negative feed—back mechanism.
Culture and characterization of arteriolar smooth muscle cells from the
rabbit renal cortex. J. C. Dussaule, J. Perez, D. Chansel, R. Ardaillou,
INSERM 64, Hôpilal Tenon, Paris, France. Cell cultures were per-
formed from collagenase—digested renal cortex of rabbits after purifica-
tion of an arteriole—rich fraction by successive sievings. Under the
conditions of culture used (10% CO2 atmosphere), smooth muscle cells
rapidly grew whereas the other cell lines disappeared. A homogeneous
culture of these cells was obtained through successive passages (2—6).
They were identified as smooth muscle cells from their spindle—shape
morphology and the presence of myofibrils with dense bodies under
electron microscopy and also from their content in creatine kinase (1612
771 mIU/mg protein; N = 18) which was 60 times higher than that of
the initial cortical homogenate. These smooth muscle cells of arteriolar
origin synthesized P012 (6.7 3.9 ng/tug/24 hr) and PGE2 (14.5 8.2
ng/mg/24 hr; N = 8). They exhibited /3-adrenergic receptors as demon-
strated by the stimulatory effect of isoproterenol on their cyclic AMP
content (437 124 and 34.7 8.7prnol/mg with and without 200 /.M
isoproterenol, respectively). These cells also synthesized and released
renin. Renin activity measured from angiotensin I formed in the
presence of rabbit plasma devoid of renin was 5.9 2.6 ng Al/hr/mg (N
= 24) in the cell extracts. Active renin in the medium represented only
17% of that in the cells. This percentage reached 76% after acidification,
which indicates that inactive renin was secreted for the most part.
Specificity of renin activity assay was demonstrated by the high
inhibitory effect of SR 42128, a specific blocker of the enzyme. Culture
of smooth muscle cells from the renal cortical arterioles represents a
new tool for the study of the synthetic functions and the receptors of
these cells and thus for a better knowledge of the cortical circulation.
Antigenicity of glomerular basement membrane (BGM) in hereditary
nephritis. C. S. 0. Savage, L. H. Noel, M. C. Gubler, R. Charbonneau,
J. P. Grunfeld, C. M. Lockwood, Royal Postgraduate Medical School,
Hammersmith Hospital London, U.K., Hôpital Necker, Paris, France.
In 20 of 42 patients with hereditary progressive glomerulonephritis
(NH), absence of or reduced binding was observed on immunofluores-
cence immunoperoxidase staining of renal tissue, with those antibodies
directed towards the Goodpasture autoantigen, namely human anti-
glomerular basement membrane (GBM) autoantibodies (HuAb) and a
monoclonal anti-human OBM antibody (MCA-Pl). HuAb and MCA-Pl
recognize the same 6 bands (between 22 and 54 Kd) in collagenase
solubilized GBM (CS-GBM) following Western blotting. The antigeni-
city of the GBM in HN has been investigated further using collagenase
digests of kidney from 3 patients with NH (CS-HNK) or 3 control
end—stage kidneys (CS-ESK) and autoantibody containing sera (HNAb)
from 4 patients with HN who developed anti-GBM nephritis following
transplantation. In Western blotting studies, HuAb (6) and MCA-Pl
showed the same binding patterns to CS-GBM and CS-ESK. However
these reagents showed a different staining pattern on CS-HNK with
absence of 3 of the 6 bands, comprising bands of 26, 30 and 54 Kd. The
binding of the 4 NHAb to CS-GBM were dissimilar. Three showed
identical binding to that seen with HaAb and MCA-Pl (to the 6 bands
between 22 and 54 Kd), the fourth binds only to bands 26, 30 and 54 Kd,
suggesting either heterogeneity in the HN Ab response to allografted
kidneys or that a difference exists in the GBM determinants present i
some patients with Alport's syndrome, a difference which may under-
line the clinical heterogeneity of the disease. Thus, our results show a
relative rather an absolute loss of Goodpasture antigenicity within GBM
of HN kidneys and imply that at least some of the gene encoding the
Goodpasture antigen are probably normal. It is suggested that an
abnormality resides in a gene which either encodes an enzyme respon-
sible for linking the antigenic moiety of one set of antigen—carrying
determinants or encodes that part of a subset of parent molecules to
which the Goodpasture antigenic determinant normally binds.
Membranous glomerulonephritis after diclofenac treatment. F. Schil-
linger, R. Montagnac, T. Milcent, Service de Néphrologie Hémo-
dialyse, CHG Troyes, France. Among drugs inducing nephrotic
syndrome (NS), nonsteroidal anti-inflammatory drugs (NSAID) are
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preponderant. They often induce the development of a minimal change
glomerulopathy with or without associated interstitial nephritis, but
only rarely cause membranous glomerulonephritis. We report a case of
reversible membranous glomenilonephritis due to diclofenac adminis-
tration. A 75-year—old man had been treated with diclofenac, 100 mg
daily, for 45 days, because he suffered from degenerative joint disease
of the knees. He presented with NS (7 kg wt increase) hypertension
(170/100mm Hg) and mild renal failure (serum creatinine 145 tmol/liter,
creatinine clearance 60 mI/mm). Immunological and etiological results
were negative and histological examination revealed membranous gb-
merulonephritis. Diclofenac treatment had been discontinued immedi-
ately after admission; diuretics induced edema regression and NS
remitted in 7 months, without corticosteroid or immunosuppressive
therapy. NSAID related membranous glomerulonephritis has been
reported in only 3 other cases; twice with dicbofenac, once with
ketoprofen. On the other hand, association of NS and acute renal
failure, with minimal glomerular changes and severe tubulointerstitial
lesions, is more and more often recognized during NSAID therapy.
Isolated NS with minimal glomerular changes and without interstitial
nephritis are also known. These side effects of NSAID, of late appear-
ance in comparison with those due to inhibition of prostaglandin—medi-
ated vasodilatation, seem to be immunologically mediated and present
individual susceptibilities related to genetic factors. Indeed, the two
other cases of diclofenac—related membranous glomerulonephritis in
the literature developed in patients with rheumatoid arthritis, an immu-
nological condition known to favor circulating immune complex forma-
tion in the presence of excess drug antigens.
IgE antibodies to isocyanates in dialysis patients. F. Lavaud, S.
Lavaud, 0. Toupance, A. Berthier, J. Chanard, Centre Hospitalier et
Universitaire, Reims, France. Isocyanates whichare chemicals used in
the dialyzer—manufacturing process are well—known inducers of asthma
in occupationaly exposed workers. However, allergy to isocyanates
resulting from blood exposure has not been reported. Sensitization to
these molecules was investigated in chronically hemodialyzed patients.
Two groups were selected: group I, 9 patients having reactions charac-
teristic of immediate—type hypersensitivity when starting dialysis;
group II, 67 dialyzed patients without anaphylactic reactions. Eleven
patients in this group had a history of atopy. IgE antibodies to
isocyanates were detected using radioallergosorbent tests (RAST) for
toluene diisocyanate, diphenylmethane diisocyanate, hexamethylene
diisocyanate and by in vitro degranulation of purified human basophils
(HBDT). In addition, sensitization to formaldehyde and ethylene oxide
was investigated. In symptomatic patients IgE antibodies to isocyan-
ates were detected at a significant level in 4 of 9 (44%) patients with
RAST and in 9 of 9 with HBDT (100%). In patients without anaphylac-
tic reactions only 7 (9%) and 9 (13%) patients had specific antibodies to
isocyanates detected with RAST and HBDT, respectively. Sensitiza-
tion to formaldehyde was detected in 1 patient of group I and in 2
patients of group II. Sensitization to ethylene oxide was detected in 2
patients of group I and in 3 patients of group II. Data show the
widespread sensitization to isocyanates in patients exposed to hemodi-
alysis, especially in patients with anaphylactic reactions where neither
formaldehyde nor ethylene oxide can be implicated. Further studies are
required to assess the specificity and the sensitivity of the tests in
uremia.
Duration of protective effect of hepatitis B vaccine in staff and patients
of dialysis centers: Determination of the optimal time for revaccination.
P. Jungers, A. M. Couroucé, A. Laplanche, E. Benhamou, F. Tron,
Department of Nephrology, Necker Hospital and Centre National de
Transfusion Sanguine, Paris, and Department of Medical Statistics,
Inst it ut Gustave Roussy, Vil/ejuif and Direction des Recherches
Cliniques Pasteur—Vacc ins, Marnes la Coquette, France. In an attempt
to define the best revaccination strategy, we analyzed the long—term
course of anti-HBs antibody (Ab) titers in medical staff and hemodial-
ysis patients of French dialysis units protected with HEVAC B (Pas-
teur) vaccine. Of the 184 healthy staff members who participated in a
multicenter efficacy trial (Lancet i:455, 1981), 143 received a first
booster injection (BI) 15 months after 3 initial subcutaneous injections
of 5 pg and were followed—up for 5 years. The mean (geometric) titer of
Ab determined 1, 21, 43 and 60 months following BI was 13,940, 1626,
592 and 492 mIU/ml, respectively. After 5 years, 93% of subjects still
had a residual (protective) titer  10 mIU/ml, including 85% with titer
 50 mIU/ml. The slope of Ab decline following BI was biphasic,
initially rapid (about 10-fold from 1 to 21 months) and then slower
(about 3-fold from 21 to 60 months). All individual time—curves were
parallel with a mean slope of — 0.108 Log/month from Ito 21 months.
Of the 215 hemodialysis patients who entered an immunogenicity trial
(C/in Nephrol2l:143, 1984), 182 received a booster 14 months after the
first injection and were followed—up for 2 years. Among those who
received a reinforced protocol, Ab titer determined 1, 6, 12 and 24
months following BI was 3282, 1142, 559 and 312 mIU/ml in group 11(3
x 10 jcg) and 2047, 914, 387 and 150 mIU/rnl in group III (4 x 5 cg).
After 2 years, 20% of groups II and III patients pooled together had a
residual titer lower than 10 mIU/mI. Also, the slope of Ab decline was
parallel in all subjects with a mean rate of — 0.107 Log/month and near
10-fold decline from 1 to 24 months. Time-curves of Ab decay for
different levels of peak Ab titers are presented on diagrams allowing the
individual determination of the residual Ab titer at any time following
booster. In conclusion, in staff personnel and patients of dialysis units
exposed to high risk of HBV infection and thus requiring sustained
effective protection, titration of anti-HBs Ab level obtained after
primovaccination is needed to assess protective efficacy and to evaluate
the optimal time for revaccination.
The rate of progression of chronic renal failure in the various types of
primary kidney diseases: A study of 167 cases. P. Jungers, A. Ferhat, Ph.
Chauveau, G. Albouze, T. Loubaris, T. Hannedouche, Department of
Nephrology, Necker Hospital, Paris. We retrospectively analyzed the
spontaneous rate of progression of renal failure (RF) from an advanced
stage, defined by plasma creatinine concentration (Pcr) of 500 cmol/liter
towards maintenance hemodialysis (HD), in all patients suffering from
primary chronic nephropathy with established diagnosis, having had at
least 6 Pcr determinations throughout this time interval and receiving
usual diet prescriptions. Among 625 patients who started HD at Necker
Hospital from January 1981, to December 1985, 167 (93 males, 74
females) fulfilled these criteria and were analyzed. The primary
nephropathy was chronic glomerulonephritis (CGN) in 55, chronic
pyelonephritis (CPN) in 42, polycystic kidney disease (PKD) in 35,
angionephrosclerosis (ANS) in 22, Alport's syndrome (AS) in 9 and
non-insulin dependent diabetes nephropathy (DN) in 4. In all patients
were recorded the time duration from Pcr 500 cmol/liter until HD
(500-HD) and from Pcr 700 mol/liter until HD (700-HD), and the mean
slope of 1/Cr (expressed in .cmol/liter x 100 per month). Mean (± 1
SEM) values observed in the different types of renal disease are shown
in the table.
No 500—HD 700—HD 1/Cr slope
CGN 55 14.3 1.5 6.3 0.8 —0.0157 0.0019
CPN 42 19.4 2.0 8.0 1.1 —0.0087 0.0012
PKD 35 17.2 1.1 6.9 0.9 —0.0064 0.0005
ANS 22 11.6 1.4 3.8 0.5 —0.0133 0.0026
AS 9 9.3 1.5 4.3 1.4 —0.0171 0.0046
DN 4 9.2 2.6 1.7 0.5 —0.0362 0.0183
Total 167 15.4 0.8 6.3 0.4 —0.0120 0.0009
The mean values of 500-HD and 700-HD were significantly longer in
CPN and PKD groups than in the CGN group, with the shorter courses
being observed in ANS, AS and DN groups. The terminal rate of
progression, expressed as the ratio 700-HD/500-HD, was accelerated in
the ANS and DN groups (ratio < 0.40) when compared to the other
groups (ratio  0.40). In conclusion, the spontaneous rate of progres-
sion of advanced chronic RF towards end—stage differs according to the
type of the underlying renal disease. Our results provide epidemiologic
baseline data for evaluating the possible effects of diet manipulation on
the progression of RF in future trials.
Extrarenal epuration (E.R.E.) in salicylate intoxications. R.
Montagnac, F. Schillinger, T. Mi/cent. A. Dinh, B. Brones, CHG
Troyes, France. We hemodialyzed a 23-year—old patient for severe
salicylate poisoning (ingestion of 40 g). He was comatos and presented
with high blood salicylate level (1500 mg/liter) and hypoprothrom-
430 Abstracts
binemia (25.8%). We emphasize the advantages, in certain circum-
stances of severe salicylism, of E.R.E. which induces a decreased
blood level and consequently much better prognosis. (1.) Deaths are
still too frequent while E.R.E. is very efficient for intoxication by
aspirin. Aspirin has a small molecular weight, diffuse mainly
extracellularly and is slightly bound to proteins. (2.) When its intrinsic
risks are considered, indications of E.R.E. are various, linked to
absorption rate, blood salicylate level, acid—base disturbances, hypo-
prothrombinemia, central neurologic manifestations and eventual asso-
ciated renal failure. (3.) Apart from hemofiltration, which has not been
adequately assessed but is certainly interesting, we consider hemodial-
ysis the better active treatment if material is available. Its efficiency is
higher than peritoneal dialysis, even if both correct associated distur-
bances (hypothermia, acidosis, metabolic disorders) in contrast to
hemoperfusion. The latter, although as efficient as hemodialysis, pre-
sents several of its own disadvantages that reserve it, for some authors,
to poisoning with other drugs that are more dangerous and/or have a
different pharmacology.
